Announcements Trials
Browse Landscape

Phase

Phase NA 30Phase 1 12Phase 2 10Phase EARLY_PHASE1 6Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 5OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 155Carboplatin 146Gemcitabine 140Nivolumab 135Paclitaxel 129Cisplatin 119Dexamethasone 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Positron-Emission Tomography × Clear all
NCT02348749 2025-03-19

18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
48 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡